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Abstract 
 
The endocannabinoid system plays a key role in female reproduction, including implantation, 
decidualization and placentation. A growing number of studies indicate that placental and 
peripheral blood anandamide levels correlate closely with both spontaneous miscarriage and 
ectopic pregnancy. Anandamide has also been implicated in blood pressure regulation. In this 
study, we aimed to determine circulating anandamide levels in preeclampsia for the first time 
in the literature. Forty-three preeclamptic patients and 71 healthy pregnant women were 
involved in this case-control study. Serum anandamide concentrations were determined by 
high performance liquid chromatography-mass spectrometry (HPLC-MS) technique. Serum 
total soluble fms-like tyrosine kinase-1 (sFlt-1) and biologically active placental growth factor 
(PlGF) levels were measured by electrochemiluminescence immunoassay. For statistical 
analyses, non-parametric methods were applied. Serum levels of anandamide were 
significantly lower in preeclamptic patients than in healthy pregnant women (0.75 (0.44-1.03) 
ng/ml versus 1.30 (0.76-2.0) ng/ml, p<0.001). Preeclamptic patients had significantly higher 
sFlt-1 levels (12121 (7963-18316) pg/ml versus 2299 (1393-3179) pg/ml, p<0.001) and 
significantly lower PlGF concentrations (71.2 (39.2-86.4) pg/ml versus 256.8 (181.1-421.0) 
pg/ml, p<0.001) as compared to healthy pregnant women. Serum anandamide concentrations 
did not correlate with serum levels of sFlt-1 and PlGF in our healthy pregnant and 
preeclamptic groups. In conclusion, we demonstrated for the first time in the literature that 
serum anandamide concentrations are decreased in women with preeclampsia. However, the 
cause and consequence of this observation remain to be determined. 
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Introduction 
Preeclampsia is a pregnancy-specific disorder, characterized by hypertension and 
proteinuria developing after the 20
th
 week of gestation in previously normotensive women, 
with a worldwide incidence of 3-8%.
1
 It is among the leading causes of maternal, as well as 
perinatal morbidity and mortality, even in developed countries. Despite extensive research, 
the etiology and pathogenesis of preeclampsia are not completely understood. Increasing 
evidence suggests that an exaggerated maternal systemic inflammatory response to pregnancy 
with an increase in the ratios of peripheral blood Th1/Th2 and Th17/regulatory T cells, a 
systemic oxidative stress, as well as an imbalance between circulating angiogenic and anti-
angiogenic factors plays a crucial role in the pathogenesis of the disease.
2-16
 
Endocannabinoids are endogenous ligands that bind to the similar receptor as delta-9-
tetrahydrocannabinol (Δ9-THC), the most potent psychotropic constituent of marijuana. The 
most studied endocannabinoid is N-arachidonoylethanolamine (also known as anandamide), 
which is reported to play a central role in female reproduction, particularly in 
decidualization,
17
 oviductal transport,
18
 preimplantation embryo development,
19
 timely 
embryo implantation and ensuring receptive uterine environment.
20
 Tightly regulated 
anandamide levels are critical for reproductive success, which are accomplished through on-
demand enzyme synthesis by the N-acylphosphatidylethanol-amine-specific phospholipase D 
(NAPE-PLD) and degradation via fatty acid amide hydrolase (FAAH).
21
 Anandamide binds 
to the cannabinoid receptors type 1 and 2 (CB1 and CB2), which exert their effects through 
various signaling pathways including adenylyl cyclase inhibiton leading to decreased cyclic 
adenosine monophosphate (cAMP) levels, activation of mitogen-activated protein kinases 
(MAPK), and either activation or inhibition of different ionic channels.
22
 
Various pathological reproductive conditions are associated with dysregulated 
anandamide levels. In mice, higher anandamide levels inhibit blastocyst differentiation, 
oviductal transport, implantation and trophoblast proliferation.
23
 Studies have shown that low 
FAAH and high CB1 expression in human placenta characterize spontaneous miscarriage,
24
 
whereas both low FAAH and CB1 expressions causing high anandamide levels in Fallopian 
tubes may play a role in ectopic implantation.
25
 High maternal peripheral blood 
endocannabinoid levels modulated by low FAAH activity in lymphocytes can inhibit 
successful pregnancy after in vitro fertilization,
26, 27
 and were recently associated with ectopic 
pregnancy possibly through tubal dysfunction.
28
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 Endocannabinoids have also been implicated in blood pressure regulation.
29
 
Endocannabinoids can cause vasodilation through CB1, TRPV1 and NO-mediated or NO-
independent mechanisms.
30
 Anandamide exerts its vasorelaxant effect on endothelial cells in 
various ways, such as by upregulating the expression and activity of the inducible NO 
synthase (NO-mediated pathway).
31
 In the cerebral circulation, CB1 also has vasodilatory 
effects directly on vascular smooth muscle by inhibiting calcium entry through L-type 
calcium channels.
32
 
While a growing number of studies indicate that placental and peripheral blood 
anandamide levels correlate closely with both spontaneous miscarriage and ectopic 
pregnancy, there are no data regarding the association between circulating endocannabinoid 
levels and preeclampsia. In this study, we aimed to determine circulating anandamide levels 
in preeclampsia for the first time in the literature. 
 
Methods 
 
Study participants 
 Forty-three preeclamptic patients and 71 normotensive, healthy pregnant women with 
uncomplicated pregnancies were involved in this case-control study. The study participants 
were enrolled in the First Department of Obstetrics and Gynecology, at the Semmelweis 
University, Budapest, Hungary. All women were Caucasian and resided in the same 
geographic area in Hungary. The preeclamptic patients and healthy pregnant women were 
matched on the basis of maternal age and gestational age at blood draw, and they were 
selected accordingly from a larger cohort of preeclamptic patients and healthy pregnant 
women. Exclusion criteria were multifetal gestation, chronic hypertension, diabetes mellitus, 
autoimmune disease, angiopathy, renal disorder, maternal or fetal infection and fetal 
congenital anomaly. The women were fasting, none were in active labor, and none had 
rupture of amniotic membranes. 
 Preeclampsia was defined by increased blood pressure (≥140 mmHg systolic or ≥90 
mmHg diastolic on ≥2 occasions at least 6 hours apart) that occurred after the 20th week of 
gestation in a woman with previously normal blood pressure, accompanied by proteinuria 
(≥0.3 g/24h or ≥1 + on dipstick in the absence of urinary tract infection). Blood pressure 
returned to normal by the 12
th
 postpartum week in each preeclamptic study patient. 
Preeclampsia was regarded as severe if any of the following criteria was present: blood 
pressure≥160 mmHg systolic or ≥110 mmHg diastolic, or proteinuria≥5 g/24h (or ≥3 + on 
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dipstick). Early onset of preeclampsia was defined as onset of the disease before the 34
th
 week 
of gestation (between the 20
th
 and 33
rd
 completed gestational weeks). An infant was 
considered small-for-gestational-age (SGA) if the birth weight was below the 10
th
 percentile 
for gestational age and gender, according to a Hungarian birth weight percentile table.
33
 
 The study protocol was approved by the Regional and Institutional Committee of 
Science and Research Ethics of the Semmelweis University, and written informed consent 
was obtained from each patient. The study was conducted in accordance with the Declaration 
of Helsinki. 
 
 
Laboratory methods 
Maternal blood samples were obtained from an antecubital vein into plain tubes (with 
no additive) and centrifuged at room temperature with a relative centrifugal force of 3000 g 
for 10 minutes. The aliquots of serum were stored at -80 °C until the measurements. 
Serum anandamide concentrations were determined by high performance liquid 
chromatography-mass spectrometry (HPLC-MS) technique. Serum samples were 
supplemented with internal standard solution (100 ng/ml D4-anandamide), and analytes were 
extracted with acetonitrile. The clear supernatant was evaporated in N2, and re-dissolved 
samples were analysed by HPLC-MS technique. The quantitation was carried out with 
calibration curve, calibration points were obtained from blank serum samples spiked with 
different concentration of anandamide. The calibration range was between 0.1 and 100 ng/ml 
anandamide. HPLC system consisted of a Jasco X-LC binary pump and autosampler. The 
quantitation was performed using TSQ Quantum Discovery triple quadrupole mass 
spectrometer with electrospray ionization source operated in positive ion mode. Analytes 
were separated using reversed-phase liquid chromatography on a Merck Purospher Star C18 
column with gradient elution. (Mobile phases were 100 mM ammonium-acetate (0.1% formic 
acid) and methanol at a flow rate of 300 µl/min.) 
Serum total soluble fms-like tyrosine kinase-1 (sFlt-1) and biologically active 
placental growth factor (PlGF) levels were measured by electrochemiluminescence 
immunoassay (Elecsys, Roche, Mannheim, Germany, Cat. No. 05109523 and 05144671, 
respectively) on a Cobas e 411 analyzer (Roche, Mannheim, Germany). 
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Statistical analysis 
 The normality of continuous variables was assessed using the Shapiro-Wilk’s W-test. 
As the continuous variables were not normally distributed, non-parametric statistical methods 
were applied. To compare continuous variables between two groups, the Mann-Whitney U-
test was used. The Fisher exact and Pearson χ2 tests were performed to compare categorical 
variables between groups. The Spearman rank order correlation was carried out to calculate 
correlation coefficients. As serum levels of anandamide, sFlt-1 and PlGF showed skewed 
distributions, we performed analyses of covariance (ANCOVA) with logarithmically 
transformed data. 
Statistical analyses were carried out using the following software: STATISTICA 
(version 11; StatSoft, Inc., Tulsa, Oklahoma, USA) and Statistical Package for the Social 
Sciences (version 22 for Windows; SPSS, Inc., Chicago, Illinois, USA). For all statistical 
analyses, p<0.05 was considered statistically significant. 
In the article, data are reported as median (interquartile range) for continuous variables 
and as number (percentage) for categorical variables. 
 
Results 
 
Patient characteristics 
 The clinical characteristics of the study participants are shown in Table 1. There were 
no statistically significant differences in terms of maternal age, gestational age at blood 
sampling and the percentage of smokers between the two study groups. The pre-pregnancy 
body mass index (BMI), the systolic and diastolic blood pressures and the percentage of 
primiparas were significantly higher, whereas the gestational age at delivery and the fetal 
birth weight were significantly lower in the preeclamptic group than in the control group. 
Fetal growth restriction was absent in healthy pregnant women, whereas it occurred in 12 
cases in the preeclamptic group. Twenty-seven women had severe preeclampsia and 20 
patients experienced early onset of the disease. 
 
Laboratory parameters 
 The laboratory parameters of the study subjects are displayed in Figure 1, 2 and 3. 
Serum levels of anandamide were significantly lower in preeclamptic patients than in healthy 
pregnant women (0.75 (0.44-1.03) ng/ml versus 1.30 (0.76-2.0) ng/ml, p<0.001; Figure 1). 
Preeclamptic patients had significantly higher sFlt-1 levels (12121 (7963-18316) pg/ml versus 
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2299 (1393-3179) pg/ml, p<0.001; Figure 2) and significantly lower PlGF concentrations 
(71.2 (39.2-86.4) pg/ml versus 256.8 (181.1-421.0) pg/ml, p<0.001; Figure 3) as compared to 
healthy pregnant women. The differences in the above laboratory parameters between the two 
study groups remained significant even after adjustment for maternal age, gestational age at 
blood draw, pre-pregnancy BMI and the percentage of primiparas in analyses of covariance 
(ANCOVA). 
 In the group of preeclamptic patients, no statistically significant differences were 
found in serum anandamide levels between patients with mild and severe preeclampsia, 
between patients with late and early onset of the disease, or between preeclamptic patients 
with and without an SGA infant (data not shown). Serum sFlt-1 concentrations were 
significantly higher in patients with early onset preeclampsia than in those with late onset 
disease (14606 (12239-24333) pg/ml versus 7971 (5991-12805) pg/ml, p<0.001). In addition, 
preeclamptic patients with fetal growth restriction (41.1 (28.0-73.2) pg/ml) or early onset of 
the disease (41.1 (23.8-68.7) pg/ml) had significantly lower PlGF concentrations than those 
without IUGR (77.3 (48.2-93.2) pg/ml, p<0.05) or with late onset disease (80.3 (66.0-99.4) 
pg/ml, p<0.001). 
 We also investigated whether the clinical characteristics of the study participants 
presented in Table 1 were related to their serum anandamide levels by calculating the 
Spearman rank order correlation coefficients (continuous variables) or by the Mann-Whitney 
U-test (categorical variables). In healthy pregnant women, serum anandamide concentrations 
showed significant positive correlations with pre-pregnancy BMI (R=0.33, p<0.05). 
Accordingly, in the healthy pregnant group, overweight and obese women (BMI≥25 kg/m2) 
had significantly higher serum anandamide levels than those with normal weight (1.80 (1.20-
2.60) ng/ml versus 1.06 (0.70-1.61) ng/ml, p<0.05). There was no other relationship between 
clinical features of the study subjects and their serum anandamide levels in either study group. 
Furthermore, serum anandamide concentrations did not correlate with serum levels of sFlt-1 
and PlGF in our healthy pregnant and preeclamptic groups. 
 
Discussion 
 In this study, we measured circulating levels of anandamide along with those of sFlt-1 
and PlGF in normal pregnancy and preeclampsia. According to our findings, serum 
anandamide levels are decreased in women with preeclampsia. However, circulating levels of 
anandamide were not related to those of angiogenic factors in preeclampsia. 
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 In the healthy pregnant group, we found a significant positive correlation between pre-
pregnancy BMI and anandamide levels. In accordance, anandamide concentrations were 
significantly higher among overweight and obese healthy pregnant women. This observation 
is consistent with earlier findings, which demonstrated a link between overactivated 
endocannabinoid system and obesity. Activation of the central endocannabinoid system 
increases food intake and promotes weight gain. In addition, a strong negative correlation was 
found between FAAH expression in human adipose tissue and circulating anandamide 
levels.
34, 35
 CB1 agonists increasing lipoprotein lipase activity and ultimately enhancing 
lipogenesis in mouse adipocytes in vitro may explain how anandamide redounds to obesity 
with a peripheral mechanism.
36
 However, we did not find such an association in the 
preeclamptic group. In fact, we even observed lower anandamide levels despite of higher pre-
pregnancy BMI. This indicates that other processes may account for changes in circulating 
anandamide levels in preeclampsia. 
 In our previous study, we determined CB1, CB2 and FAAH expressions and 
localization in placental samples from healthy and preeclamptic women.
37
 According to our 
findings, CB1 expression measured by Western blotting was markedly stronger in 
preeclamptic placenta, and these findings were confirmed by strong CB1 immunoreactivity in 
various placental localizations, including syncytiotrophoblasts. Therefore, decreased serum 
concentration of anandamide in preeclampsia might be a consequence of its sequestration in 
the placenta by binding to syncytiotrophoblasts overexpressing CB1. Nevertheless, Abán et 
al. detected similar CB1 protein expression in normal and preeclamptic placental tissues.
38
 
 Earlier studies have shown that leptin stimulates FAAH activity in human T-
lymphocytes
39
 and human lymphoma cells.
40
 Furthermore, IL-6 also increases FAAH activity 
in human lymphocytes.
41
 Both leptin and IL-6 serum levels are elevated in preeclampsia.
7, 42
 
Thus, increased lymphocyte FAAH expression and activity mediated by leptin or IL-6 might 
be another candidate, which is responsible for decreased circulating anandamide levels in 
preeclampsia. Further studies are needed to clarify this issue with measurement of lymphocyte 
FAAH expression in the peripheral blood of preeclamptic and healthy pregnant women. 
 Heat shock protein 70 and albumin can act as cytosolic anandamide-binding 
proteins.
43
 We have recently reported that Hsp70 serum levels are elevated in PE.
44-46
 It is also 
possible that Hsp70 as a chaperone binds anandamide in the peripheral circulation leading to 
its decreased serum levels. Moreover, by binding to albumin, anandamide could be excreted 
through the kidneys with loss of albumin in the urine. Nevertheless, we did not find any 
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relationship between circulating anandamide levels and the degree of proteinuria in our 
preeclamptic pregnant women. 
Recent findings indicate a central role of circulating angiogenic factors and their 
antagonists in the pathogenesis of preeclampsia.
3
 In this study, we also measured serum sFlt-1 
and PlGF concentrations in normal pregnancy and preeclampsia by electrochemiluminescence 
immunoassay. However, increased sFlt-1 and decreased PlGF levels were not related to serum 
anandamide concentrations in women with preeclampsia, suggesting that alterations in 
circulating levels of angiogenic factors and anandamide are independent processes in 
preeclampsia. 
Both exogenous and endogenous cannabinoids have been reported to exert anti-
inflammatory effects. Anandamide attenuates Th17-mediated inflammation through in vivo 
increasing IL-10 production, which induces different microRNAs targeting pro-inflammatory 
cytokines and leading to IL-17 and IFN-γ reduction.47 Endocannabinoids also mediate 
cytokine shift from Th1 to Th2 cytokines by suppression of cell activation, inhibition of pro-
inflammatory cytokine production and NF-κB dependent apoptosis.48 Both anandamide and 
exogen Δ9-THC increase regulatory T cell (Treg) functions through CB1 and CB2, resulting 
in significant suppression of inflammatory cytokines and chemokines.
49
 Therefore, it is 
tempting to speculate that decreased circulating anandamide levels might contribute to the 
development of the excessive systemic inflammatory response and the increase in the ratios of 
peripheral blood Th1/Th2 and Th17/regulatory T cells characteristic of the maternal syndrome 
of the disease. 
Chronic activation of the endocannabinoid system results in complex cardiovascular 
effects, primarily in bradycardia, decrease of blood pressure and myocardial contractility, 
mediated by CB1 via stress signaling and cell death leading to decreased contractility.
50
 
Underlying mechanisms involve modulation of autonomic outflow through presynaptic 
autonomic nerve terminals and the central nervous system, as well as direct myocardial 
effects.
30
 Vasodilatory effects may involve CB1 and TRPV1 receptor- and NO-mediated or 
NO-independent pathways. Thus, it is also possible that decreased serum anandamide 
concentration might play a role in blood pressure elevation in preeclampsia. Although we did 
not find a significant correlation between anandamide levels and blood pressure values in our 
preeclamptic group, even sFlt-1 and PlGF levels were not related to blood pressure values or 
the severity of the disease, indicating that regulation of blood pressure is more complex in this 
pregnancy-specific disorder. Interestingly, in a recent study, increased angiotensin II 
contraction of the uterine artery at early gestation in a transgenic rat model of preeclampsia 
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was reduced by inhibition of anandamide hydrolysis, suggesting that renin-angiotensin 
system-endocannabinoid system interactions may contribute to the enhanced vascular 
reactivity in early stages of hypertensive pregnancy.
51
 
In our study, the similar serum anandamide levels of preeclamptic patients regardless 
of the severity, the time of onset of the disease or the presence of an SGA infant might be 
explained by the complex etiology of preeclampsia. Several genetic, behavioural and 
environmental factors need to interact to produce the complete picture of this pregnancy-
specific disorder. We reported various genetic and soluble factors that were associated with 
the severity or complications of preeclampsia, including HELLP syndrome and fetal growth 
restriction.
45, 52-54
 Nevertheless, it is also possible that the relatively small sample size of the 
preeclamptic group prevented to detect an effect in the subgroup analyses. 
 In conclusion, we demonstrated for the first time in the literature that serum 
anandamide concentrations are decreased in women with preeclampsia. However, the cause 
and consequence of this observation remain to be determined. 
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Figure legends 
 
Figure 1. 
Serum anandamide levels of healthy pregnant women and preeclamptic patients (p<0.001) 
Middle line: median; Box: interquartile range (25-75 percentile); Whisker: range (excluding 
outliers) 
 
Figure 2. 
Serum soluble fms-like tyrosine kinase-1 (sFlt-1) levels of healthy pregnant women and 
preeclamptic patients (p<0.001) 
Middle line: median; Box: interquartile range (25-75 percentile); Whisker: range (excluding 
outliers) 
 
Figure 3. 
Serum placental growth factor (PlGF) levels of healthy pregnant women and preeclamptic 
patients (p<0.001) 
Middle line: median; Box: interquartile range (25-75 percentile); Whisker: range (excluding 
outliers) 
 
 
 
